272 related articles for article (PubMed ID: 37019110)
1. An updated atlas of antibody evasion by SARS-CoV-2 Omicron sub-variants including BQ.1.1 and XBB.
He Q; Wu L; Xu Z; Wang X; Xie Y; Chai Y; Zheng A; Zhou J; Qiao S; Huang M; Shang G; Zhao X; Feng Y; Qi J; Gao GF; Wang Q
Cell Rep Med; 2023 Apr; 4(4):100991. PubMed ID: 37019110
[TBL] [Abstract][Full Text] [Related]
2. Defining a de novo non-RBM antibody as RBD-8 and its synergistic rescue of immune-evaded antibodies to neutralize Omicron SARS-CoV-2.
Rao X; Zhao R; Tong Z; Guo S; Peng W; Liu K; Li S; Wu L; Tong J; Chai Y; Han P; Wang F; Jia P; Li Z; Zhao X; Li D; Zhang R; Zhang X; Zou W; Li W; Wang Q; Gao GF; Wu Y; Dai L; Gao F
Proc Natl Acad Sci U S A; 2023 Dec; 120(52):e2314193120. PubMed ID: 38109549
[TBL] [Abstract][Full Text] [Related]
3. Immune evasion of neutralizing antibodies by SARS-CoV-2 Omicron.
Wang L; Møhlenberg M; Wang P; Zhou H
Cytokine Growth Factor Rev; 2023 Apr; 70():13-25. PubMed ID: 36948931
[TBL] [Abstract][Full Text] [Related]
4. Broad protective RBD heterotrimer vaccines neutralize SARS-CoV-2 including Omicron sub-variants XBB/BQ.1.1/BF.7.
Zhang Y; Kang X; Liu S; Han P; Lei W; Xu K; Xu Z; Gao Z; Zhou X; An Y; Han Y; Liu K; Zhao X; Dai L; Wang P; Wu G; Qi J; Xu K; Gao GF
PLoS Pathog; 2023 Sep; 19(9):e1011659. PubMed ID: 37721934
[TBL] [Abstract][Full Text] [Related]
5. Neutralization of EG.5, EG.5.1, BA.2.86, and JN.1 by antisera from dimeric receptor-binding domain subunit vaccines and 41 human monoclonal antibodies.
He Q; An Y; Zhou X; Xie H; Tao L; Li D; Zheng A; Li L; Xu Z; Yu S; Wang R; Hu H; Liu K; Wang Q; Dai L; Xu K; Gao GF
Med; 2024 May; 5(5):401-413.e4. PubMed ID: 38574739
[TBL] [Abstract][Full Text] [Related]
6. Rapid escape of new SARS-CoV-2 Omicron variants from BA.2-directed antibody responses.
Dijokaite-Guraliuc A; Das R; Zhou D; Ginn HM; Liu C; Duyvesteyn HME; Huo J; Nutalai R; Supasa P; Selvaraj M; de Silva TI; Plowright M; Newman TAH; Hornsby H; Mentzer AJ; Skelly D; Ritter TG; Temperton N; Klenerman P; Barnes E; Dunachie SJ; ; Roemer C; Peacock TP; Paterson NG; Williams MA; Hall DR; Fry EE; Mongkolsapaya J; Ren J; Stuart DI; Screaton GR
Cell Rep; 2023 Apr; 42(4):112271. PubMed ID: 36995936
[TBL] [Abstract][Full Text] [Related]
7. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants.
Wang Q; Iketani S; Li Z; Liu L; Guo Y; Huang Y; Bowen AD; Liu M; Wang M; Yu J; Valdez R; Lauring AS; Sheng Z; Wang HH; Gordon A; Liu L; Ho DD
Cell; 2023 Jan; 186(2):279-286.e8. PubMed ID: 36580913
[TBL] [Abstract][Full Text] [Related]
8. Immune evasion, infectivity, and fusogenicity of SARS-CoV-2 BA.2.86 and FLip variants.
Qu P; Xu K; Faraone JN; Goodarzi N; Zheng YM; Carlin C; Bednash JS; Horowitz JC; Mallampalli RK; Saif LJ; Oltz EM; Jones D; Gumina RJ; Liu SL
Cell; 2024 Feb; 187(3):585-595.e6. PubMed ID: 38194968
[TBL] [Abstract][Full Text] [Related]
9. Distinct patterns of SARS-CoV-2 BA.2.87.1 and JN.1 variants in immune evasion, antigenicity, and cell-cell fusion.
Li P; Liu Y; Faraone JN; Hsu CC; Chamblee M; Zheng Y-M; Carlin C; Bednash JS; Horowitz JC; Mallampalli RK; Saif LJ; Oltz EM; Jones D; Li J; Gumina RJ; Liu S-L
mBio; 2024 May; 15(5):e0075124. PubMed ID: 38591890
[TBL] [Abstract][Full Text] [Related]
10. Neutralization sensitivity of SARS-CoV-2 Omicron variants FL.1 and GE.1 by therapeutic antibodies and XBB sera.
Lee J; Naoe Y; Bang U; Nakagama Y; Saito A; Kido Y; Hotta A
Virology; 2024 Jul; 595():110067. PubMed ID: 38653156
[TBL] [Abstract][Full Text] [Related]
11. Key mechanistic features of the trade-off between antibody escape and host cell binding in the SARS-CoV-2 Omicron variant spike proteins.
Li W; Xu Z; Niu T; Xie Y; Zhao Z; Li D; He Q; Sun W; Shi K; Guo W; Chang Z; Liu K; Fan Z; Qi J; Gao GF
EMBO J; 2024 Apr; 43(8):1484-1498. PubMed ID: 38467833
[TBL] [Abstract][Full Text] [Related]
12. A panel of multivalent nanobodies broadly neutralizing Omicron subvariants and recombinant.
Zheng L; Wang H; Liu X; Xu C; Tian M; Shi G; Bai C; Li Z; Wang J; Liu S
J Med Virol; 2024 Mar; 96(3):e29528. PubMed ID: 38501378
[TBL] [Abstract][Full Text] [Related]
13. Identification of a highly conserved neutralizing epitope within the RBD region of diverse SARS-CoV-2 variants.
Wang Y; Yan A; Song D; Duan M; Dong C; Chen J; Jiang Z; Gao Y; Rao M; Feng J; Zhang Z; Qi R; Ma X; Liu H; Yu B; Wang Q; Zong M; Jiao J; Xing P; Pan R; Li D; Xiao J; Sun J; Li Y; Zhang L; Shen Z; Sun B; Zhao Y; Zhang L; Dai J; Zhao J; Wang L; Dou C; Liu Z; Zhao J
Nat Commun; 2024 Jan; 15(1):842. PubMed ID: 38287016
[TBL] [Abstract][Full Text] [Related]
14. A bispecific antibody exhibits broad neutralization against SARS-CoV-2 Omicron variants XBB.1.16, BQ.1.1 and sarbecoviruses.
Wang Y; Hao A; Ji P; Ma Y; Zhang Z; Chen J; Mao Q; Xiong X; Rehati P; Wang Y; Wang Y; Wen Y; Lu L; Chen Z; Zhao J; Wu F; Huang J; Sun L
Nat Commun; 2024 Jun; 15(1):5127. PubMed ID: 38879565
[TBL] [Abstract][Full Text] [Related]
15. A Recombinant Protein XBB.1.5 RBD/Alum/CpG Vaccine Elicits High Neutralizing Antibody Titers against Omicron Subvariants of SARS-CoV-2.
Thimmiraju SR; Adhikari R; Villar MJ; Lee J; Liu Z; Kundu R; Chen YL; Sharma S; Ghei K; Keegan B; Versteeg L; Gillespie PM; Ciciriello A; Islam NY; Poveda C; Uzcategui N; Chen WH; Kimata JT; Zhan B; Strych U; Bottazzi ME; Hotez PJ; Pollet J
Vaccines (Basel); 2023 Oct; 11(10):. PubMed ID: 37896960
[TBL] [Abstract][Full Text] [Related]
16. Continued evasion of neutralizing antibody response by Omicron XBB.1.16.
Faraone JN; Qu P; Zheng YM; Carlin C; Jones D; Panchal AR; Saif LJ; Oltz EM; Gumina RJ; Liu SL
Cell Rep; 2023 Oct; 42(10):113193. PubMed ID: 37777967
[TBL] [Abstract][Full Text] [Related]
17. Neutralization of SARS-CoV-2 BA.2.86 and JN.1 by CF501 adjuvant-enhanced immune responses targeting the conserved epitopes in ancestral RBD.
Liu Z; Zhou J; Wang W; Zhang G; Xing L; Zhang K; Wang Y; Xu W; Wang Q; Man Q; Wang Q; Ying T; Zhu Y; Jiang S; Lu L
Cell Rep Med; 2024 Mar; 5(3):101445. PubMed ID: 38428429
[TBL] [Abstract][Full Text] [Related]
18. Broadly neutralizing antibodies against sarbecoviruses generated by immunization of macaques with an AS03-adjuvanted COVID-19 vaccine.
Feng Y; Yuan M; Powers JM; Hu M; Munt JE; Arunachalam PS; Leist SR; Bellusci L; Kim J; Sprouse KR; Adams LE; Sundaramurthy S; Zhu X; Shirreff LM; Mallory ML; Scobey TD; Moreno A; O'Hagan DT; Kleanthous H; Villinger FJ; Veesler D; King NP; Suthar MS; Khurana S; Baric RS; Wilson IA; Pulendran B
Sci Transl Med; 2023 May; 15(695):eadg7404. PubMed ID: 37163615
[TBL] [Abstract][Full Text] [Related]
19. Antibody evasion associated with the RBD significant mutations in several emerging SARS-CoV-2 variants and its subvariants.
Bhattacharya M; Chatterjee S; Lee SS; Dhama K; Chakraborty C
Drug Resist Updat; 2023 Nov; 71():101008. PubMed ID: 37757651
[TBL] [Abstract][Full Text] [Related]
20. Less neutralization evasion of SARS-CoV-2 BA.2.86 than XBB sublineages and CH.1.1.
Hu Y; Zou J; Kurhade C; Deng X; Chang HC; Kim DK; Shi PY; Ren P; Xie X
Emerg Microbes Infect; 2023 Dec; 12(2):2271089. PubMed ID: 37824708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
